Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

957
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
957
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

875
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
875
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

62
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
62
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

82
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
82
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

315
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
315
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using Stakeholder Input to Develop a Best Practice Advisory (BPA) to Increase Prescribing of Automated Insulin Delivery (AID) Systems for People With Type 1 Diabetes (PwT1D).

Journal of diabetes science and technology·2026
Same author

Swimming With the Omnipod 5 Automated Insulin Delivery System: An Observational Investigation of Swimmers With Type 1 Diabetes in the Omnipod 5 Pivotal Trial.

Diabetes, obesity & metabolism·2026
Same author

Clinically distinct metabotypes of pediatric MASLD identified through unsupervised clustering of NASH CRN data.

Nature communications·2026
Same author

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Mediates the Impact of Diabetes on Adverse Outcomes in Coronary Artery Disease.

Diabetes care·2026
Same author

Accuracy of Dexcom G6 Pro Continuous Glucose Monitor in the Intensive Care Setting: TIGHT ICU G6 Study.

Diabetes technology & therapeutics·2025
Same author

Diabetes technology use in U.S. hospitals: A survey of user experiences.

Diabetes, obesity & metabolism·2025
Same journal

A Pilot Study on Disposal Practices and Environmental Awareness of Insulin-Related Devices Among People With Diabetes.

Journal of diabetes science and technology·2026
Same journal

Quality of In-Use Insulin Under Real-World Storage Conditions in Mwanza, Tanzania.

Journal of diabetes science and technology·2026
Same journal

Continuous Glucose Monitoring Metrics for Predicting Adverse Neonatal Outcomes in Individuals Undergoing Gestational Diabetes Screening.

Journal of diabetes science and technology·2026
Same journal

Diabetes Technologist: Optimal Use of Technology in Everyday Practice.

Journal of diabetes science and technology·2026
Same journal

AI-Driven Diabetes Care and Its Relevance in the Philippine Context: Opportunities and Persistent Digital Barriers.

Journal of diabetes science and technology·2026
Same journal

Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes.

Journal of diabetes science and technology·2026
See all related articles

Related Experiment Video

Updated: Mar 2, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.4K

Inpatient Use of Automated Insulin Delivery Systems.

Laya Chadalawada1, Rohit Parab1, Jenna M Feeley2

  • 1Division of Endocrinology, Emory University School of Medicine, Atlanta, GA, USA.

Journal of Diabetes Science and Technology
|March 1, 2026
PubMed
Summary
This summary is machine-generated.

Automated insulin delivery (AID) systems show promise for inpatient diabetes care, improving glycemic control and safety. Hospitals need to address operational and regulatory challenges for wider adoption.

Keywords:
AID use in hospitalautomated insulin deliveryclosed-loop systems in hospitalinpatient AIDinpatient glycemic control

More Related Videos

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

10.9K
Hippocampal Insulin Microinjection and In vivo Microdialysis During Spatial Memory Testing
10:32

Hippocampal Insulin Microinjection and In vivo Microdialysis During Spatial Memory Testing

Published on: January 11, 2013

17.1K

Related Experiment Videos

Last Updated: Mar 2, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.4K
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

10.9K
Hippocampal Insulin Microinjection and In vivo Microdialysis During Spatial Memory Testing
10:32

Hippocampal Insulin Microinjection and In vivo Microdialysis During Spatial Memory Testing

Published on: January 11, 2013

17.1K

Area of Science:

  • Diabetes Technology
  • Endocrinology
  • Clinical Informatics

Background:

  • Automated insulin delivery (AID) systems enhance outpatient diabetes management.
  • Inpatient settings present challenges with glycemic control and insulin needs.

Purpose of the Study:

  • To review the feasibility and safety of AID systems in inpatient settings.
  • To identify barriers to implementing AID systems in hospitals.

Main Methods:

  • Narrative review of peer-reviewed studies on inpatient AID use.
  • Included hospital-initiated and continued outpatient AID devices.
  • Covered both medical and surgical patient populations.

Main Results:

  • AID systems appear feasible and safe for inpatients, improving time in range.
  • No significant increase in hypoglycemia observed with AID use.
  • Implementation is hindered by EHR integration, interoperability, and policy issues.

Conclusions:

  • Hospitals should prepare for increased inpatient AID use by developing infrastructure and policies.
  • Evaluating hospital-initiated AID is crucial for managing complex hyperglycemia.
  • Addressing operational and regulatory barriers is key for successful integration.